need help? call toll free 877-866-7400 chat now chat now

toll free phone 877-866-7400

COVID-19 TESTS In Stock - Order HERE  BD | CARESTART | CLARITY | QUIDEL

Access Bio RCHM-02071 CareStart COVID-19 Antigen Rapid Test, 20/kit

By Access Bio | Mfr#: RCHM-02071 | Tiger#: TM108690

Highlights

  • Rapid detection of SARS-CoV-2
  • Fast results in 10 minutes
  • Identifies with 88.4% sensitivity and 100% specificity
  • Authorized by the FDA under EUA [Emergency Use Authorization]
  • CLIA waived
List Price: $550.00
$265.00
You Save: $285.00 - 52%

 

  • Volume Discounts

    QtyPrice
    3$243.80
Availability:In Stock
Free Shipping (USA)
Ships Out Within: 24 - 48 Hours
This product is only allowed to a Medical Professional

Overview for Access Bio RCHM-02071 CareStart COVID-19 Antigen Rapid Test, 20/kit

The CareStart COVID-19 Antigen Covid-19 Test is a lateral flow immunochromatographic assay for the detection of extracted nucleocapsid protein antigens specific to SARS-CoV-2 in swab specimens directly collected from symptomatic individuals who are suspected of COVID-19 by their healthcare providers.

Due to the highly contagious nature and global health crisis, SARS-CoV-2 has been designated as a pandemic by the World Health Organization (WHO) and continues to have devastating impacts on healthcare systems and the world economy including the U.S. To effectively end the SARS-CoV-2 pandemic, systematic screening and detection of both clinical and asymptomatic COVID-19 cases is critical.

The CareStart Antigen test covers proteins of variants such as B.1.1.7 (Alpha), B.1.351 (Beta), B.1.1.248 (Gamma), B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.617.3, AY.1 (Delta plus), C.37 (Lambda).

As an intended point-of-care (POC) designated test with a 10 minute processing time, CareStart™ COVID-19 Antigen Test allows effective screening of COVID-19 infection on a large scale.

  • Lateral flow assay
  • Rapid results in 10 minutes
  • Nasopharyngeal swab specimen collection
  • Intended at POC setting (i.e., in patient care settings) by medical professionals operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation
  • Detect SARS-CoV-2 nucleocapsid protein antigen
  • Identify acute infection in symptomatic patients with 88.4% sensitivity and 100% specificity
  • Designated as a CLIA waived tests